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Calcium ions serve multiple biological roles; therefore, main-
taining a nearly constant extracellular ionized calcium concen-
tration (Ca2,) is a critical function of free-living terrestrial
organisms. Tetrapods have evolved a homeostatic system for
accomplishing this goal that has two key elements [1] (Fig. 1): The
first are cells that "sense" (that is, recognize and respond to) small
physiologically-relevant changes in Ca2, including parathyroid
cells and thyroidal C-cells, which secrete, respectively, less para-
thyroid hormone (PTH) and more calcitonin (CT) in the presence
of elevated levels of Ca20 [1, 21. The second element are the
effector tissues that translocate Ca20 ions in response to calcio-
tropic hormones (that is, kidney, bone and intestine) [1, 2]. The
receptor-mediated mechanisms through which classical calciotro-
pie hormones, such as PTH, calcitonin and 1,25-dihydroxyvitamin
D regulate their target tissues has been the focus of intense
studies. In contrast, much less has been known until recently
about the mechanisms underlying Ca20-sensing by parathyroid
and C-cells. Recent application of molecular techniques, however,
has shown that Ca2)-sensing, like the sensing of many other
extracellular first messengers, involves a cell surface, Ca20-
sensing receptor (CaR) that is a member of the superfanuly of
G-protein-coupled receptors (GPCR) [3]. Moreover, the receptor
is present not only in classic Ca20-sensing cells, like parathyroid
cells, but also in effector elements of the mineral ion homeostatic
system, such as the kidney [3, 4]. Finally, studies on the role of the
CaR in inherited diseases of Ca20-sensing have yielded novel
insights into the basis for previously poorly understood direct
actions of Ca20 on renal function.
Indirect evidence that parathyroid and kidney cells sense
Ca20 through a cell surface receptor
Elevated levels of Ca20 modify intracellular second messen-
gers in parathyroid cells in a manner very similar to that of
so-called, "Ca2-mobilizing" hormones (such as thyrotropin re-
leasing hormone) in their target tissues [1, 5—7]. For instance,
raising Ca20 stimulates phospholipase C (PLC), leading to
accumulation of inositol 1,4,5-trisphosphate (1P3) [7], which then
elevates the cytosolic calcium concentration (Cat) by mobilizing
Ca2 from intracellular stores [5]. These results suggested that
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Ca20 might regulate parathyroid function via a cell surface,
calcium-mobilizing receptor [1, 5—7]. Ca20 also produces a
pertussis toxin-sensitive inhibition of intracellular cAMP accumu-
lation, consistent with coupling of the putative Ca20-sensing
receptor to adenylate cyclase via the inhibitory G-protein G [8].
Ca20 also directly affects a number of additional cell types,
including several types of renal cells [1]. Effects of Ca20 on the
kidney include reducing glomerular filtration rate, exerting a
diuretic action in the proximal tubule and inhibiting the actions of
antidiuretic hormone [9—11]. Moreover, elevated levels of peritu-
bular but not luminal Ca20 or Mg20 inhibit Ca2 and Mg2
reabsorption in the thick ascending limb [12]. Some of the renal
actions of Ca2 are reminiscent of those of Ca2 on parathyroid
function. For example Ca20 produces a pertussis toxin-sensitive
inhibition of vasopressin-stimulated cAMP accumulation in the
medullary and cortical thick ascending limb of Henle's loop [13].
These data raised the possibillty that certain renal cells might
express Ca20-sensing receptors, which could specifically regulate
certain aspects of renal function.
Isolation of cDNAs encoding bovine parathyroid and rat renal
Ca20-sensing receptors (CaRs) using expression cloning in
Xenopus kievis oocytes
Xenopus laevis oocytes represent a convenient and effective
vehicle for isolation by expression cloning of full length cDNAs
for calcium-mobilizing hormone receptors because the latter
couple to an endogenous G-protein-activated PLC following
injection of their messenger RNAs (mRNAs). Indeed, injection of
X laevis oocytes with bovine parathyroid mRNA renders them
responsive to Ca20 [14, 15], suggesting that the same technique
could be utilized to clone a PLC-coupled, Ca20-sensing receptor.
Functional screening of a cDNA library prepared from bovine
parathyrold mRNA led to isolation of a single full length clone of
a Ca20-sensing receptor (BoPCaR) [3]. The latter was then used
to screen a rat kidney eDNA library and isolate a highly homol-
ogous, rat kidney Ca20-sensing receptor (RaKCaR) [4], which
likely represents the rat homologue of the same ancestral gene.
The two receptors show similar pharmacological profiles, with an
order of potency for Ca20-sensing receptor agonists (Gd3 >
neomycin> Ca2 > Mg2) nearly identical to that of the native
receptor in bovine parathyroid cells [3]. BoPCaR and RaKCaR
likewise each produce agonist-dependent increases in 1P3 and Ca
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Fig. 1. Diagram showing how calcium acts as an &tracellular messenger (its actions are shown as dashed lines), similar to the more classical calciotropic
hormones PTH and 1,25-dihydrmyvitamin D (whose actions are shown by solid lines), in the calcium ion homeostatic system. Abbreviations are: Ca2,
calcium; P04, phosphate; ECF, extracellular fluid; PTH, parathyroid hormone; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D;
plus signs represent positive actions and minus signs inhibitoiy effects. Reproduced from Brown EM, Pollack M, Hebert SC: Cloning and
characterization of extracellular Ca2-sensing receptors from parathyroid and kidney: Molecular physiology and pathophysiology of Ca2-sensing. The
Endocrinologist 4:419—426, 1994 (with permission).
in oocytes as well as in mammalian cells, consistent with their
coupling to PLC [3]. Recent studies document that the receptor
also inhibits cAMP accumulation in human embryonic kidney
(1-IEK) cells (K. Rogers et al, unpublished observations) suggest-
ing that this single receptor isoform could mediate the actions of
Ca20 on both P1 turnover and cAMP metabolism in parathyroid
and kidney cells.
The deduced amino acid sequence of BoPCaR and RaKCaR
predict three major domains (Fig. 2). The first is a large (> 600
amino acid) extracellular aminoterminus with a 20 amino acid
signal peptide. A second, 250 amino acid domain follows with
seven predicted membrane-spanning helices characteristic of the
superfamily of GPCRs. The third C-terminal domain of —200
amino acid is presumbaly cytoplasmic [3, 4]. It is not yet known
where cationic agonists bind to the CaR, although this probably
occurs in the extracellular domain. The latter lacks high affinity
calcium-binding motifs, such as the EF hands present in calmodu-
un and other intracellular receptors for calcium. Such binding
sites would be persistently occupied by the ambient, millimolar
levels of Ca2 present in the extracellular fluid and therefore
would not be conducive to sensing Ca20. The extracellular
domain of BoPCaR has several highly acidic regions that poten-
tially represent binding sites for calcium and other cationic ligands
similar to other low affinity Ca2-binding proteins (such as
calsequestrin) [3]. The CaRs only have significant sequence
homology with the metabotropic glutamate receptors (mUluRs)
[3, 4] that are receptors for glutamate, the major excitatory
neurotransmitter in the central nervous system [16]. O'Hara et at
[17] and Conklin and Bourne [18] have suggested that the
extracellular domains of the CaR and the mGluRs may resemble
those of the bacterial periplasmic binding proteins. The latter are
involved in sensing and/or transporting extracellular ligands into
bacteria including nutrients and polyvalent anions and cations
(such as phosphate) [19]. Thus the Ca20-sensing receptor could
have evolved from an ancient family of cell surface proteins
essential for sensing a variety of extracellular ligands [18].
Tissue distribution of the CaR
Transcripts for the CaR are heavily expressed in tissues known
to sense Ca20 including paratliyroid, C-cells and kidney. It is not
currently understood how the same receptor can apparently
mediate both the inhibition of PTH secretion and stimulation of
CT secretion by elevated levels of Ca20. Receptor transcripts are
also present in several other tissues including intestine, pituitary
and brain. Some of these (such as brain) are not thought to play
any role in the regulation of mineral ion homeostasis. It is of
interest, however, that changes in brain cell activity induce
changes in Ca20 within the local brain cell enviromnent due to
increased uptake of Ca2 by brain cells. This raises the possibility
that Ca2-sensing plays as yet undefined role in regulating brain
cell function. Ruat et al [20] have recently shown that a CaR clone
isolated from rat brain is essentially identical to RaKCaR and
appears to be present in nerve endings where it could potentially
regulate synaptic function.
Intrarenal localization of the CaR
Recent studies utilizing immunohistochemistry with specific
antiCaR antibodies, in situ hybridization as well as reverse tran-
scriptase-based PCR on defined microdissected segments of the
nephron have delineated the intrarenal distribution of the CaR in
the rat. The receptor is present in the MTAL, CTAL, distal
convoluted tubule (DCT), cortical collecting duct (CCD) as well
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Fig. 2. Schematic diagram illustrating the major structural features of the predicted BoPCaR protein. Symbols are shown in the key. The diagram also
indicates the mutations that have been described in the disorders of familial hypocalciuric hypercalccmia (FHH) and autosomal dominant hypocalcemia
(see text for details). Reprinted from Brown EM, Pollak M, Seidman CE, Seidman JO, Chou Y-HW, Riccardi D, Hebert SC: Calcium-ion-sensing
cell-surface receptors. N EngI J Med 333:234 to 240, 1995 (with permission).
as in the inner medullary (IMCD) and papillary collecting duct
(D. Riccardi et al, manuscript submitted for publication). In the
CTAL where the receptor is particularly heavily expressed, it
appears to be present predominantly on the basolateral surface of
the cell while in the IMCD it is located on the apical membrane.
The distribution of the CaR in rat kidney overlaps with that of the
PTH receptor in CTAL and DCT (Riccardi et al, manuscript
submitted for publication).
Inherited human diseases of CaR shed light on its role in
regulating parathyroid and renal function
Inactivating mutations
Genetic diseases can illuminate not only the molecular basis for
a particular disease state but also the normal physiological role(s)
of a gene. It seemed plausible that mutations in the CaR gene
could cause diseases of Ca2 homeostasis that would manifest
abnormal Ca2,-sensing by parathyroid cells and other cell types
expressing the CaR. Indeed, familial hypocalciuric hypercalcemia
(FHH) and neonatal severe hyperparathyroidism (NSHPT) share
features indicating that they could be inherited diseases of
Ca20-sensing. FHH [21] is an autosomal dominant disorder with
a benign clinical course and few of the usual signs and symptoms
of hypercalcemia. Affected individuals have mild to moderate
hypercalcemia associated with abnormal recognition and/or han-
dling of Ca20 by parathyroid and kidney suggesting abnormal
Ca20-sensing [21]. NSHPT, in contrast, presents a severe neo-
natal hypercalcemia due to hyperparathyroidism that is often fatal
unless total parathyroidectomy is carried out shortly after birth.
The availability of the CaR clone made it possible for Pollak,
Brown and Chou to use an RNase protection assay utilizing
probes derived from the normal human CaR gene to identii'
point mutations in the coding region of the receptor gene in three
families with FHH [22], including one in which there was an
individual with NSHPT who was homozygous for that family's
mutation. Subsequent studies have confirmed the presence of
missense mutations (that is, substitution of one amino acid for
another) in most families with FHH in whom the abnormal gene
is linked to the long arm of chromosome 3 [23, 24]. The disorder
is not genetically homogenous, however, as an apparently similar
phenotype is linked to chromosome 19 in one family [25], while in
a second, linkage to the loci on both chromosomes 3 and 19 has
been excluded [26]. In these latter two families the identity of the
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abnormal genes is not yet known. Pollak et a! engineered the
mutation (arg79otrp) into the wild-type bovine CaR and demon-
strated nearly complete loss of its biological activity when ex-
pressed in X laevis oocytes [221. Subsequent preliminary studies
have suggested variable loss of biological activity of receptors
harboring FHH mutations within the extracellular domain of the
CaR [27]. Thus FHH and NSHPT appear to result from inacti-
vating mutations in the CaR when present in the heterozygous
and homozygous states, respectively, and represent the clinical
marnifestations of mild and severe "resistance" of certain target
tissues to Ca2,. In the case of the parathyroid cell mild and
severe reduction in responsiveness of PTH secretion to Ca2'0
have been documented in FHH [281 and NSHPT, respectively
[291.
Activating mutations
More recently Pollak et al [30] and subsequently other investi-
gators [31] have documented missense mutations in the coding
region of the CaR in families with autosomal dominant hypocal-
cemia that had previously been characterized as having a form of
hypoparathyroidism. In contrast to the inactivating mutations in
FHH dominant hypocalcemia activate the CaR [301. The hypocal-
cemia in this syndrome presumably results from abnormal sensing
of overt hypocalcemia as "normal" by the parathyroid glands of
affected family members. They retain the capacity to show en-
hanced PTH secretion as Ca2,, decreases further, however,
thereby producing stable hypocalcemia, The definition of the
molecular basis for both FHH and autosomal dominant hypocal-
eemia has helped to explain certain clinical features of these
disorders and in turn to clarify several previously poorly under-
stood direct effects of Ca20 on renal function. Individuals with
FHH show markedly enhanced renal tubular reabsorption of
calcium and magnesium [21] that contributes to their hypercalce-
mia and in some cases mild hypermagnesemia (some patients with
untreated NSHPT have more marked hypermagnesemia, while
individuals with autosomal doinnant hypocaleemia can have hy-
pomagnesemia consistent with the CaR contributing to "setting"
not only the level of Ca20, hut also of Mg2 ). This abnormal
renal tubular divalent cation handling persists even following
parathyroidectomy, indicating that it is an inherent renal abnor-
mality that is independent of PTH [32]. Such parathyroidecto-
mized individuals with FHH do not increase their renal calcium
excretion during saline infusion, although they do show increased
calcium excretion following administration of the loop diuretic
ethacrynic acid. In view of the localization of the CaR in the
MTAL and CTAL, it appears likely that the receptor plays an
important role in regulating renal tubular reabsorption of calcium
in these nephron segments at least in part by counteracting the
stimulatory effects of PTH on the latter parameter in the CTAL.
Conversely, affected individuals from families with activating
mutations causing autosomal dominant hypocalcemia appear
unduly prone to nephrocalcinosis and impairment of renal func-
tion when attempts are made to normalize their serum calcium
concentration presumably because of marked hypercaleiuria due,
in part, to inappropriately reduced renal tubular reabsorption of
calcium resulting from an overactive CaR in this nephron seg-
ment. That is, they suffer the usual renal complications of
hypercalcemia when normocalcemic because of increased renal
"sensitivity" to Ca2,,.
Another renal consequence of chronic hyperealcemia is a
reduced maximal urinary concentrating ability. Of interest, indi-
viduals with FHH concentrate their urine normally despite being
hyperealcemie [33], while patients with autosomal dominant hy-
pocalcemia due to CaR activating mutations can develop neph-
rogenic diabetes insipidus even when normocalcemic. We there-
fore postulate that the CaR mediates the effects of Ca20 on renal
concentrating capacity and that this mechanism is a means of
coordinating renal calcium and water handling. That is, a calcium
load will promote calciuria, in part through actions on basolateral
CaRs in the CTAL. However, apical CaRs block maximal urinary
concentrating ability in the distal collecting duet, thereby diluting
the increased load of calcium in a larger volume of urine, to
reduce the subsequent risk of stone formation in this situation. It
remains to he determined whether the CaR mediates additional
actions of calcium on renal function such as changes in GFR or
renal blood flow.
Summary and future prospects
Changes in the expression, structure and function of this and
perhaps other extracellular Ca2,-sensing receptors could also be
involved in other diseases. The abnormal Ca2,-sensing in pri-
mary and secondary (uremic) hyperparathyroidism [34], for, ex-
ample, has recently been shown to be associated with reductions
in the level of expression of the CaR. Drugs are currently being
tested which activate the cloned CaR and may represent an
effective form of therapy for primary hyperparathyroidism [35].
The renal toxicity caused by certain drugs could also be related to
actions on CaRs. Aminoglycoside antibiotics for instance have
toxic actions on the kidney that might potentially result, in part,
from inappropriately sustained activation of renal CaRs. The
development of antagonists to the CaR might provide a means of
reducing or eliminating such toxicity.
Further understanding of the functions of the CaR in its various
target tissues will likely provide additional insights into their roles
in health and disease. We essentially know nothing, for instance,
of the role of the CaR in brain. There could well be additional
CaRs which act through other second messenger pathways or via
totally different effector systems such as the modulation of ion
channels. A protein expressed on parathyroid, proximal renal
tubule and placental cells has recently been cloned which may
represent another Ca2,,-sensor [36, 37]. In the proximal tubule,
for example, it is a candidate for mediating the inhibitory effects
of elevating Ca20 on the 1-hydroxylation of vitamin D. Finally
one or more forms of CaR could also play a role in mediating
several longer-term actions of Ca240 on cellular function such as
the regulation of gene expression, cellular differentiation or
cellular proliferation [1].
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